article
Innovation in real-time next-generation sequencing provides pharmaceutical benefits
Tim Sandle explains how next-generation sequencing (NGS) could aid in the development of novel antimicrobials to overcome multi-drug resistance.
List view / Grid view
Sepsis
Filter the results
news
First COVID-19 patient enrolled in acute kidney injury drug trial
AM-Pharma has announced the enrolment and financing of a COVID-19 cohort in its Phase III acute kidney injury treatment trial.
news
IL-6 signalling blockade alleviates severe COVID-19 symptoms
Scientists have shown that treating COVID-19 patients with severe respiratory complications with an IL-6 signalling inhibitor improved their symptoms.
news
UK launches scheme to encourage development of novel antibiotics
The NHS is offering two contracts to pay pharma companies at the start of their research into antibiotics, to promote the development of new antimicrobials.
news
Scientists develop rapid test that determines antibiotic resistance
Scientists in Germany have developed a test using electric fields and Raman spectroscopy to ascertain specific antibiotic resistance of pathogens and thus enable the prescription of effective treatment.
news
Thermo Fisher Scientific to showcase unique ability to assess sepsis risk
Thermo Fisher Scientific Inc., the world leader in serving science, today announced that it will showcase its clinical assay for Procalcitonin (PCT), which aids in the risk assessment of critically ill patients with sepsis, at the Society of Critical Care Medicine (SCCM) 40th Critical Care Conference 2011.